Back to Newsroom
Back to Newsroom

SHAREHOLDER ALERT: PTLA GERN AAN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Wednesday, 04 March 2020 10:45 AM

The Law Offices of Vincent Wong

Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / March 4, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/portola-pharmaceuticals-inc-loss-submission-form?prid=5581&wire=1
Lead Plaintiff Deadline: March 16, 2020
Class Period: May 8, 2019 to January 9, 2020

Allegations against PTLA include that: (1) Portola's internal control over financial reporting regarding reserve for product returns was not effective; (2) Portola was shipping longer-dated product with 36-month shelf life; (3) Portola had not established adequate reserve for returns of prior shipments of short-dated product; (4) as a result, Portola was reasonably likely to need to "catch up" on accounting for return reserves; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Geron Corporation (NASDAQ:GERN)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/geron-corporation-et-al-loss-submission-form?prid=5581&wire=1
Lead Plaintiff Deadline: March 23, 2020
Class Period: March 19, 2018 to September 26, 2018

The filed complaint alleges that defendants misled investors regarding a drug called imetelstat, which was intended to treat certain cancers that occur in bone marrow. Specifically, defendants misled investors about the results of a clinical drug study of imetelstat called IMbark. That study was designed to ascertain whether imetelstat helped patients with a cancer called myelofibrosis.

Aarons, Inc. (NYSE:AAN)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/aarons-inc-loss-submission-form?prid=5581&wire=1
Lead Plaintiff Deadline: April 28, 2020
Class Period: March 2, 2018 to February 19, 2020

Allegations against AAN include that: (i) Aaron's had inadequate disclosure controls, procedures, and compliance measures; (ii) consequently, the operations of Aaron's Progressive Leasing ("Progressive") and Aaron's Business ("AB") segments were in violation of the Federal Trade Commission ("FTC") Act and/or relevant FTC regulations; (iii) consequently, Aaron's earnings from those segments were partially derived from unlawful business practices and were thus unsustainable; (iv) the full extent of Aaron's liability regarding the FTC's investigation into its Progressive and AB segments, Aaron's noncompliance with the FTC Act, and the likely negative consequences of all the foregoing on the Company's financial results; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]

SOURCE: The Law Offices of Vincent Wong

Topic:
Lawsuits
Back to newsroom
Back to Newsroom

Contact Us Today


If you have questions or want to learn more about our products, our team’s here to help!

Share by: